SENORES Share Price Target 2030

CAGR-based price projection for Senores Pharmaceuticals Limited (SENORES) targeting 2030, derived from official NSE exchange closing prices.

Bear Case (25.7% CAGR)
Rs 3,372
2030 Target
Base Case (64.3% CAGR)
Rs 9,836
2030 Target
Bull Case (220.9% CAGR)
Rs 143,202
2030 Target

Current Market Snapshot

CMP: Rs 1,349.60
52W High: Rs 1,550.90
52W Low: Rs 821.40
1Y CAGR: 170.0%
3Y CAGR: 64.3%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,697 Rs 2,217 Rs 4,332
2028 Rs 2,133 Rs 3,643 Rs 13,902
2029 Rs 2,682 Rs 5,986 Rs 44,618
2030 Rs 3,372 Rs 9,836 Rs 143,202

Other SENORES Price Targets

2025 2026 2027 2028 2035 2040 2050

Frequently Asked Questions

What is the SENORES share price target for 2030?

Based on historical growth analysis, the SENORES share price target for 2030 ranges from Rs 3,372 (conservative) to Rs 9,836 (base case) to Rs 143,202 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of SENORES?

The current market price of SENORES (Senores Pharmaceuticals Limited) is Rs 1,349.60. The 52-week high is Rs 1,550.90 and 52-week low is Rs 821.40.

Is SENORES a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for SENORES price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 25.7% CAGR), Base (64.3% CAGR), and Bull (optimistic at 220.9% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.